Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

C International Conference on Molecular Targets and Cancer Therapeutics in a poster titled "A Phase 2 trial of SNS-595 in women with platinum refractory epithelial ovarian cancer," Abstract No. A158.

On Wednesday, October 24, 2007 at the AACR-NCI-EORTC meeting, Sunesis will present additional non-clinical data in a poster titled "SNS-595 potentiates the in vivo activity of carboplatin, cisplatin and gemcitabine in solid tumor xenografts," Abstract No. B285. This poster presentation will take place in Poster Session B -- Other Small Molecule Therapeutics.

About SNS-595

SNS-595 is a replication-dependent DNA damaging agent that causes irreversible G2 arrest and rapid apoptosis. A secondary mechanism for SNS-595 is a unique inhibition of topoisomerase II that causes highly selective DNA damage.

Data reported today build upon positive results from non-clinical studies, and from Sunesis' dose-escalating Phase 1 clinical trial of SNS-595 in which an ovarian cancer patient with advanced disease achieved a PR. In addition to the Phase 2 clinical trial in ovarian cancer patients, SNS-595 is currently being evaluated in two Phase 1b acute leukemia clinical trials. In clinical trials conducted to date, SNS-595 has been generally well tolerated and has shown objective responses in both solid and hematological tumor types. In non-clinical evaluations, SNS-595 demonstrates broad and potent activity in xenograft, syngeneic and drug-resistant models.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2007 there will be an estimated 22,430 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. The front-line treatment for ovarian cancer is typically a combination of a taxane and a platinum dru
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, ... 7,849,611) support that prevents ankle sprains by cushioning the ... it fits securely around the outside of any shoe ... & comfort while still offering protection against sprains. With ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... body temperatures of newborns with temporal artery thermometry (forehead ... (under arm) thermometry, the clinically recommended method for this ... new study reported in Advances in Neonatal Care ... clinical analysis evaluating the accuracy of temporal artery thermometry ...
... BB&T Capital Markets served as the exclusive financial advisor ... developer, manufacturer and marketer of therapeutic footwear and related ... Global, an international provider of medical device solutions for ... Vista, Calif. Dr. Comfort generated net sales of $71.8 ...
Cached Medicine Technology:Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 2Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 3BB&T Advises Dr. Comfort on Its Sale to DJO Global in Transaction Valued at $254.6 Million 2
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the ... created for kids with cancer. The Chemo Duck App, available on ... with enjoyable games to help children of all ages living with ... to keep kids entertained, educated and at ease while waiting for ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 Thousand ... Fresenius Medical Care recalled its GranuFlo and NaturaLyte dialysis ... litigation underway in U.S. District Court, District of Massachusetts, ... January 20th, the Court has remanded a case filed ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... 22, 2015 Payday lending practices in ... and cause financial distress to the states that permit ... Howard University’s Center on Race and Wealth. , While ... activity, payday loans at the same time substantially depress ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... 29 Ingenious Med, the leader in inpatient,practice ... the,company approaches exciting new milestones. Record sales and ... Ingenious Med even closer to,the 4,000 user mark, ... of,2008. In addition, the company expects to reach ...
... majority of general internists and pediatricians in the United ... for young adults with complex chronic illnesses that originate ... survey. , The survey, conducted by researchers at the ... Michigan, examined a random sample of internists and pediatricians ...
... reliable results , , TUESDAY, July 29 (HealthDay News) -- ... care and research, but most tests aren,t administered according ... Center researchers. , In cancer care, exercise tests are ... patients. In cancer research, exercise tests are most often ...
... 40 years of ... brand marketing expertise, CHICAGO, July 29 The Cambridge Group, ... firm as a director., Mr. Marineau brings 40 years of ... to the firm. He,recently retired as president and CEO of Levi ...
... YORK, July 29 Care Investment Trust Inc.,(NYSE: ... quarter 2008,financial results before the market opens on Tuesday, ... conference call on Tuesday, August 12, 2008, at,11:00 a.m. ... call may,be accessed live by dialing 800-240-7305 or by ...
... may leave a mark on the brain, by changing ... and problems with attention. For one in six Americans ... often trigger more frequent urges to urinate, such mind-body ... , "We often tend to focus on just one ...
Cached Medicine News:Health News:Ingenious Med Continues Record Customer Growth and Approaches Key Milestones 2Health News:Ingenious Med Continues Record Customer Growth and Approaches Key Milestones 3Health News:Most generalists reluctant to provide primary care for young adults with chronic illness 2Health News:Most generalists reluctant to provide primary care for young adults with chronic illness 3Health News:Exercise Testing for Cancer Fails to Follow Guidelines 2Health News:The Cambridge Group Names Philip Marineau a Director 2Health News:Findings on bladder-brain link may point to better treatments for problems in sleep, attention 2
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... The Humphrey Matrix represents the ... Using frequency doubling technology, the Humphrey ... thorough visual field evaluation and assess ... enables you to provide complete long-term ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... Great vision and disposable lens ... you have astigmatism and want crisp, clear ... lens, consider Vertex Toric. Vertex Toric lenses ... a process that produces a perfect edge ...
Medicine Products: